Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159403 · ClinicalTrials.gov registry record
A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
A clinical trial, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- 325
- Enrollment target
NCT03159403: Completed study, sponsored by Melinta Therapeutics.
NCT03159403 is a clinical trial that has completed, run by Melinta Therapeutics. The registered enrollment target is 325 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03159403 has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- 325 participants
- Enrollment target
Study Summary
This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
Primary Outcome
The Types Of Primary Infections refers to whether the primary infection was skin or skin structure or other systemic infection (for example, bacteremia, prosthetic joint infection, osteomyelitis).
Interventions
- DRUG Oritavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2017-04-12 |
| Est. Completion | 2018-03-08 |
What the finished NCT03159403 record still lists
NCT03159403 is an observational study that tracks outcomes without assigning an intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Oritavancin is the first listed.
NCT03159403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03159403 about?
NCT03159403 is a clinical study titled "A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting". This study is a retrospective, observational study to evaluate oritavancin use in participants under real world conditions.
What is the current status of trial NCT03159403?
This trial is currently completed. The enrollment target is 325 participants. The study started on 2017-04-12. Estimated completion is 2018-03-08.
What interventions are being tested in trial NCT03159403?
The interventions under investigation include: Oritavancin (DRUG).
Who is sponsoring clinical trial NCT03159403?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI